Literature DB >> 24130322

Ranolazine's sweet side--improvement of glycaemic control by the novel mechanism of skeletal muscle microvascular recruitment.

Richard L Verrier1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24130322      PMCID： PMC3810802          DOI： 10.1113/jphysiol.2013.260687

Source DB:  PubMed          Journal:  J Physiol        ISSN： 0022-3751            Impact factor:   5.182


× No keyword cloud information.
  9 in total

1.  Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs.

Authors:  Gong Zhao; Erin Walsh; John C Shryock; Eric Messina; Yuzhi Wu; Dewan Zeng; Xiaobin Xu; Manuel Ochoa; Stephen P Baker; Thomas H Hintze; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2011-06       Impact factor: 3.105

2.  Ranolazine injection into coronary or femoral arteries exerts marked, transient regional vasodilation without systemic hypotension in an intact porcine model.

Authors:  Tuomo Nieminen; Caio A M Tavares; José R M Pegler; Luiz Belardinelli; Richard L Verrier
Journal:  Circ Cardiovasc Interv       Date:  2011-09-27       Impact factor: 6.546

3.  Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.

Authors:  Adam D Timmis; Bernard R Chaitman; Michael Crager
Journal:  Eur Heart J       Date:  2005-09-21       Impact factor: 29.983

4.  Ranolazine recruits muscle microvasculature and enhances insulin action in rats.

Authors:  Zhuo Fu; Lina Zhao; Weidong Chai; Zhenhua Dong; Wenhong Cao; Zhenqi Liu
Journal:  J Physiol       Date:  2013-06-24       Impact factor: 5.182

5.  Modulation of alpha 1-adrenoceptors in rat left ventricle by ischaemia and acyl carnitines: protection by ranolazine.

Authors:  M C Allely; C M Brown; B A Kenny; A T Kilpatrick; A Martin; M Spedding
Journal:  J Cardiovasc Pharmacol       Date:  1993-06       Impact factor: 3.105

6.  Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.

Authors:  Jeffrey W Chisholm; Allison B Goldfine; Arvinder K Dhalla; Eugene Braunwald; David A Morrow; Ewa Karwatowska-Prokopczuk; Luiz Belardinelli
Journal:  Diabetes Care       Date:  2010-03-31       Impact factor: 17.152

7.  Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.

Authors:  David A Morrow; Benjamin M Scirica; Bernard R Chaitman; Darren K McGuire; Sabina A Murphy; Ewa Karwatowska-Prokopczuk; Carolyn H McCabe; Eugene Braunwald
Journal:  Circulation       Date:  2009-04-06       Impact factor: 29.690

8.  Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).

Authors:  Mikhail Kosiborod; Suzanne V Arnold; John A Spertus; Darren K McGuire; Yan Li; Patrick Yue; Ori Ben-Yehuda; Amos Katz; Philip G Jones; Ann Olmsted; Luiz Belardinelli; Bernard R Chaitman
Journal:  J Am Coll Cardiol       Date:  2013-03-10       Impact factor: 24.094

9.  Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits.

Authors:  Wei-Qun Wang; Chelsea Robertson; Arvinder K Dhalla; Luiz Belardinelli
Journal:  J Pharmacol Exp Ther       Date:  2008-03-05       Impact factor: 4.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.